TP53 and cancer: Although this is, to our knowledge, the first in-depth exploration of the impact of TP53 deficiency in cancer cells on CAR T-cell-mediated killing, our data are supported by previous studies in physiologic cytotoxic T-cells (CTLs) and natural killer (NK)-cells.